Renée St-Jean, BScPhm
For lessons in how to avoid biosimilar switching pitfalls, one need only look north to Canada. The country’s recent reliance on a nonmedical approach to this complex process caused several problems, including patient confusion, interrupted access to financial support programs and a breakdown in continuity of care, according to several experts who are familiar with the model.
Spurred by public payors looking to contain costs, Canada implemented a